海外の腎臓がんの免疫療法のベスト医師 — ページ2

タフシン・オザトリ准教授は、イスティニエ・リヴ大学病院にて乳がん、肺がん、消化器がんを専門としています。

• 腫瘍学における10年以上の経験
• アンカラ腫瘍クリニックおよびエルズルム地域研修研究病院での勤務経験
• 2016年に准教授に昇進
• セルチュク大学医学部にて研修

_doctor_10980_年以上の経験を持つ腫瘍内科教授。チチン医師は、İstinye University Liv Hospital Topkapıにて進行腎がん治療を専門としています。

• トラキア大学にて腫瘍内科のフェローシップ修了
• トラキア大学医学部にて准教授、後に教授を歴任
• 腎がんに対する免疫療法および分子標的治療において豊富な経験を持つ
• トルコ腫瘍内科学会会員

İstinye University Liv Hospital Topkapıの医療腫瘍学准教授。腎臓がんの免疫療法を専門とする。

• 米国臨床腫瘍学会（ASCO）会員
• がん治療成績に関する査読付き論文を多数発表
• 医療腫瘍学部門の教育コーディネーター
• 臨床および学術の両面で豊富な経験を持つ

オズデン医師は、コジャエリ大学医学部での専門的なトレーニングを経て、腫瘍内科において_doctor_10151_年以上の経験を有しています。

• イスタンブール大学で内科のレジデンシーを修了
• コジャエリ大学で腫瘍内科を専門とする
• バグジュラル・プライベート・サファ病院を含む複数の病院で勤務

アレムダル医師は腫瘍内科を専門とし、アクデニズ大学で広範な研修を受け、メディカルパーク・アンタルヤにて腎臓がんの免疫療法に注力しています。

• 2018年より腫瘍内科の専門医認定を取得
• 腫瘍学において_doctor_9570_年以上の経験
• アンタルヤの主要な病院複合施設に勤務

腎臓がんの免疫療法を専門とするハサン・ムトル医師は、メディカル・パーク・アンタルヤにて、標的療法と次世代遺伝子治療を組み合わせています。

• 腫瘍内科における_doctor_9526_年以上の経験
• 米国のトップクラスの腫瘍科で研修
• 腫瘍内科の准教授の称号
• 補完医療アプローチにおける専門知識

マリアム・アブ・ザイド医師は、Shefaa Al Orman国際腫瘍病院の臨床腫瘍医です。欧州臨床腫瘍学会（ESMO）の認定を受けています。アブ・ザイド医師は、固形腫瘍および血液がんの治療を専門としています。アイン・シャムス大学で臨床腫瘍学および核医学の博士号（Ph.D.）を取得しています。

• さまざまな種類のがんに対する化学療法、免疫療法、分子標的治療を実施。
• 腫瘍学の臨床試験を監督し、治療に関連する毒性を管理。
• 複雑な病期分類や診断のために、多職種チーム内で患者ケアを調整。
• 年間約6,000人の患者を治療するESMO認定センターで勤務。

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

ニール・クラインマン医師は、シェバ医療センターの結石・内視鏡泌尿器科ユニットを統括しています。複雑な腫瘍に対する腎温存レーザー手術のパイオニアです。フォーブス誌とResultMedにより、2025年および2026年のイスラエルのベストドクターに選出されました。クラインマン医師は、がん治療中に臓器機能を維持するための独自のデュアルレーザーシステムを使用しています。

• トーマス・ジェファーソン大学およびマクマスター大学で泌尿器科フェローシップを修了。
• 上部尿路がん（UTUC）、腎結石、前立腺がんに対する低侵襲治療の専門家。
• 非外科的化学アブレーションに関するOLYMPUS試験の研究者として従事。
• 米国内視鏡泌尿器科学会フェローであり、60以上の科学論文を発表。

エマド・シャシュ医師は、70件以上の腫瘍学臨床試験に参加した腫瘍内科医です。NCIの乳がん総合病院で医療ディレクターを務めています。シャシュ医師は、化学療法、分子標的療法、免疫療法を含む全身療法を専門としています。JCIの病院品質管理および患者安全に関するディプロマを保持しています。

• ESMOパネルの投票権を持つメンバーであり、ASCO委員会のメンバーでもあります。
• 乳がん、婦人科がん、泌尿生殖器がん、胸部がん、消化器がん、および希少がんを治療しています。
• ブリュッセルのEORTCで元研究医師および医療リーダーを務めました。
• 年間6,000人の患者を治療するESMO認定腫瘍学センター、Shefaa Al Ormanで勤務しています。

マハ・ヤヒア博士は、シェファ・アル・オルマン国際腫瘍病院の腫瘍内科医兼血液内科医です。エジプト軍医療隊で中佐の医師として勤務した経験があります。ヤヒア博士は、乳がん、胸部がん、消化器がんの治療計画を専門としています。免疫療法、分子標的療法、複雑な化学療法プロトコルに注力しています。

• マーディ軍事医療センター（Maadi AFMC）の臨床研究支援チームの元リーダー。
• カイロ大学国立がん研究所で血液腫瘍学の研修を修了。
• 泌尿器がん、婦人科がん、希少がん、および血液疾患の治療を行う。
• 年間6,000人の患者を治療するESMO認定センターに勤務。

トゥンカイ・タシュ医師は、イスタンブールのSafe Urologyクリニックの泌尿器科外科医です。P-Shotの応用に関する結果を発表した世界で最初の5人の医師の一人です。タシュ医師は泌尿器腫瘍学と男性の性機能健康を専門としています。ドイツのハイデルベルク大学でフェローシップを修了しました。彼の診療は、再生医療とがんのロボット手術に重点を置いています。

• 英国の認定を受けたペニス増大のための外科的手法を開発。
• トルコにPRPと幹細胞を組み合わせたペニス注射を導入。
• ロボット支援前立腺全摘除術および腎温存手術を実施。
• 国際幹細胞応用学会の会員。

アタカン・トプチュ准教授は、メディポル・アジバデム地区病院にて標的療法および免疫療法を専門としています。

• 腫瘍学に関する50以上の科学論文を発表
• 欧州臨床腫瘍学会（ESMO）会員
• がん関連の栄養失調および老年腫瘍学の専門知識
• ベズミアレム・ヴァクフ大学にて医療腫瘍学のフェローシップ修了

Ayse Irem Yasin准教授は、メディポル・アジバデム地区病院にて、腎臓がんの免疫療法を含む泌尿器がんを専門としています。

• ベズミアレム・ヴァクフ大学にて医療腫瘍学のフェローシップ修了
• 免疫療法の専門知識を持ち、多岐にわたるがん種を臨床対象とする
• ESMO（欧州臨床腫瘍学会）認定医資格を保持
• クリーブランド・クリニックやバーゼル大学病院などでの国際的な臨床研修経験

ナイル・パクソイ准教授は、メディポル・バフチェリエヴレル病院にて腎臓がんの免疫療法を専門としており、腎細胞がんに関する広範な研究を行っています。

• ESMO（欧州臨床腫瘍学会）認定の腫瘍内科専門医
• 転移性腎細胞がんの治療成績に関する研究を発表
• がんの新規治療法に関する国際的な臨床試験に参加

アブドラ・サキン医師は、メディポル・バフチェリエヴレル病院にて腎臓がんの免疫療法を専門としています。

• 腫瘍内科で_doctor_6837_年以上の経験を持ち、腎臓がんに注力
• ユズンジュ・ユル大学腫瘍内科の元部長
• イスタンブールのオクメイダヌ教育研究病院で研修
• 高度な免疫療法における豊富な経験

30,000件以上のPETスキャンを実施し、1,000人の甲状腺がん患者を治療。ボルデ医師はHCG Manavataがんセンターにて高度な核医学療法を専門としています。

• _doctor_2774_年_の核医学および腫瘍学における経験
• 放射性ヨウ素療法およびLu-177 RN療法に精通
• 複数の医学雑誌に研究論文を発表
• あらゆる種類の核医学スキャンおよびPET-CT画像診断の経験

アブドラ・サキン教授（Prof. Dr. Abdullah Sakin）は、腫瘍内科の教授です。肺がん、乳がん、消化器がん、泌尿器がん、婦人科がん、頭頸部がん、悪性黒色腫（メラノーマ）などの固形腫瘍を専門としています。

科学的根拠に基づいた個別化医療を提供しています。治療法には、化学療法、分子標的療法、免疫療法、ホルモン療法、精密腫瘍学（プレシジョン・オンコロジー）が含まれます。200本以上の科学論文を執筆しており、国際的な臨床研究にも積極的に参加しています。これらの活動は、患者中心のがん医療の発展に寄与しています。

シュリダール・P.S.医師は放射線療法の専門医であり、HCGマナヴァタがんセンターにて腎臓がんの免疫療法を含む腫瘍学の広範なトレーニングを受けています。

• 放射線療法の認定医であり、_doctor_3397_年以上の経験を持つ
• インド放射線腫瘍学会会員
• 神経腫瘍学および温熱腫瘍学を専門とする
• バナーラス・ヒンドゥー大学およびマイソール大学で研修